Press Release: Immune-Onc : Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Associatio

Strength of clinical data presented to date support a registrational CMML study PALO ALTO, Calif.--(BUSINESS WIRE)-- Immune-Onc Therapeutics, Inc. (Immune-Onc), a clinical-stage biopharmaceutical company advancing novel therapies in...